⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
KODK
RKDA
OTLK
UTHR
CLSD
AZN
BTE
CCNE
IONS
APLS
GYRO
NVS
GNTX
BLTE
JNJ
LCTX
ABBV
REGN
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK